|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2017
|
|
gptkbp:ATCCode
|
gptkb:D11AH05
|
|
gptkbp:brand
|
gptkb:Dupixent
|
|
gptkbp:CASNumber
|
gptkb:1190264-60-8
|
|
gptkbp:contraindication
|
hypersensitivity to dupilumab
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
~21 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dupilumab
|
|
gptkbp:indication
|
gptkb:prurigo_nodularis
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
moderate-to-severe asthma
moderate-to-severe atopic dermatitis
|
|
gptkbp:inhibitedBy
|
gptkb:IL-13_signaling
IL-4 signaling
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG4
|
|
gptkbp:mechanismOfAction
|
blocks IL-4 and IL-13 signaling
|
|
gptkbp:molecularWeight
|
146000 Da
|
|
gptkbp:patent
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
N/A (not assigned)
|
|
gptkbp:prescribes
|
adolescents
adults
children (age varies by indication)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
gptkb:DB12161
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
conjunctivitis
injection site reactions
eosinophilia
oral herpes
keratitis
blepharitis
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:interleukin-4_receptor_alpha
|
|
gptkbp:UNII
|
6J4J0X73CU
|
|
gptkbp:usedFor
|
gptkb:prurigo_nodularis
gptkb:atopic_dermatitis
asthma
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
|
|
gptkbp:bfsParent
|
gptkb:Il-4
gptkb:Dupixent
|
|
gptkbp:bfsLayer
|
6
|